A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects

[1]  J. Schug,et al.  RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers , 2016, Scientific Reports.

[2]  J. Rogers,et al.  Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1 , 2016, Experimental Neurology.

[3]  J. Cummings,et al.  Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.

[4]  R. Lhommel,et al.  Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[5]  Danko D. Georgiev,et al.  Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity , 2015, The Journal of Neuroscience.

[6]  G. Doblhammer,et al.  Effect of pioglitazone medication on the incidence of dementia , 2015, Annals of neurology.

[7]  C. Luan,et al.  HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. , 2015, Cell metabolism.

[8]  Chengjie Xiong,et al.  Age and amyloid effects on human central nervous system amyloid‐beta kinetics , 2015, Annals of neurology.

[9]  M. Berciano,et al.  Neuroprotective Effect of Bexarotene in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis , 2015, Front. Cell. Neurosci..

[10]  Takanori Sasaki,et al.  Positron emission tomography to elucidate pharmacokinetic differences of regioisomeric retinoid x receptor agonists. , 2015, ACS medicinal chemistry letters.

[11]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[12]  G. Landreth,et al.  Nuclear receptors in neurodegenerative diseases , 2014, Neurobiology of Disease.

[13]  G. Thatcher,et al.  Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo* , 2014, The Journal of Biological Chemistry.

[14]  Yvette I. Sheline,et al.  An Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice , 2014, Science Translational Medicine.

[15]  Steven H. Liang,et al.  Synthesis of [(11)C]Bexarotene by Cu-Mediated [(11)C]Carbon Dioxide Fixation and Preliminary PET Imaging. , 2014, ACS medicinal chemistry letters.

[16]  M. Ritsner,et al.  The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial. , 2013, The Journal of clinical psychiatry.

[17]  K. Mcfarland,et al.  Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. , 2013, ACS chemical neuroscience.

[18]  D. Wesson,et al.  Response to Comments on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[19]  Sean J. Miller,et al.  Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[20]  D. Borchelt,et al.  Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[21]  D. Holtzman,et al.  In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis , 2013, Molecular Neurodegeneration.

[22]  R. Cowan,et al.  U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T‐cell lymphoma , 2013, The British journal of dermatology.

[23]  Michael T. Heneka,et al.  PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice , 2012, The Journal of Neuroscience.

[24]  G. Landreth,et al.  Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease , 2012, The Journal of Neuroscience.

[25]  D. Holtzman,et al.  In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS , 2012, PloS one.

[26]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[27]  G. Landreth,et al.  Apolipoprotein E Promotes β-Amyloid Trafficking and Degradation by Modulating Microglial Cholesterol Levels* , 2011, The Journal of Biological Chemistry.

[28]  G. Landreth,et al.  Nuclear receptors as therapeutic targets for Alzheimer's disease , 2011, Expert opinion on therapeutic targets.

[29]  S. Mandrup,et al.  Molecular basis for gene-specific transactivation by nuclear receptors. , 2011, Biochimica et biophysica acta.

[30]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[31]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[32]  J. Renger,et al.  Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats , 2010, Molecular Neurodegeneration.

[33]  C. Wellington,et al.  ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice* , 2010, The Journal of Biological Chemistry.

[34]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[35]  R. Bateman,et al.  Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. , 2009, Analytical biochemistry.

[36]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[37]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[38]  T. Comery,et al.  The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease , 2007, Molecular and Cellular Neuroscience.

[39]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[40]  P. Tontonoz,et al.  Liver X receptors as integrators of metabolic and inflammatory signaling. , 2006, The Journal of clinical investigation.

[41]  Peter Tontonoz,et al.  Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. , 2006, Annual review of medicine.

[42]  K. Hymes,et al.  Bexarotene: a clinical review , 2004, Expert review of anticancer therapy.

[43]  S. R. Howell,et al.  Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[44]  A D Roses,et al.  APOE is a major susceptibility gene for Alzheimer's disease. , 1994, Current opinion in biotechnology.

[45]  L Zhang,et al.  Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. , 1994, Journal of medicinal chemistry.

[46]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[47]  K. Yarasheski,et al.  Reducing plasma HIV RNA improves muscle amino acid metabolism. , 2005, American journal of physiology. Endocrinology and metabolism.

[48]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[49]  N. Fitz,et al.  Neurobiology of Disease Liver X Receptor Agonist Treatment Ameliorates Amyloid Pathology and Memory Deficits Caused by High-fat Diet in App23 Mice , 2022 .